OBJECTIVES: Several treatments have received regulatory approvals to treat ovarian cancer (Ov) as a maintenance therapy after 1st line (1L) induction therapy. While these treatments have demonstrated meaningful outcomes in clinical trials, limited data is available to describe differences in patient characteristics for Ov patients that continue 1L induction therapy as 1L maintenance therapy (MTx) versus those that switch to a new MTx within a real-world population.

METHODS: 1L ovarian patients that received induction therapy were identified from LiveTracker®, a large database of patient charts across multiple oncology indications. Patients that began 1L maintenance therapy at least 6 months post-platinum-based induction therapy and had not progressed to 2L in EU4 +UK from January 2023 to April 2024 were extracted and analyzed.

RESULTS: In the Ov cohort (1L, n = 3,742), Bevacizumab was the most prescribed MTx, followed by Niraparib, Olaparib, then an Ol + Be + Ru combination. 34% of the patient cohort continued maintenance with Bevacizumab. Amongst the patients that continued maintenance, 91% (n=1,287) were BRCA wildtype and/or HRD- (HR Proficient). 66% (n=3,742) of patients switched to a new MTx and amongst those patients, 57% (n=2,455), were BRCA wildtype and/or HRD- (HR Proficient) patients. The characteristics of patients who continued Bevacizumab as MTx in combination after Bevacizumab induction therapy were compared using Chi-Square tests to those who switched to a new MTx. These populations differ significantly based on country, 1L MTx, BRCA/HRD status, CA-125 levels, radiographic progression, comorbidities, and ECOG score.

CONCLUSIONS: Contemporary and granular real-world data on the Ov maintenance treatment landscape in EU4+UK reflects significant heterogeneity in patient characteristics for those that continue MTx therapy vs. patients that switch to a new MTx therapy.